Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-11-20 10:34:20 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/S0140-6736(26)01953-7
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0140673626019537
其他信息:
出版社: Elsevier BV
作者: Ofri Mosenzon; Julio Rosenstock; José G Raya; Joseph S Grimsby; Roberto A Calle; Kevin Cannon; Amina Z Haggag; Harold Bays; Neena Sarkar; Alison Templeton; Michelle Fanous; Jennifer Lighter; Andrea Vavere; George D Yancopoulos; Boaz Hirshberg

